The Emory Alzheimer's Disease Research Center (ADRC) provides Georgia and the region with comprehensive clinical, research, and educational programs This renewal application outlines our success in building an environment that encourages and supports innovative projects directed at understanding the pathogenesis and developing new treatments for AD and other age-related cognitive disorders. We benefit from generous institutional support from Emory, one of the nation's fastest growing research academic enterprises, and collaborative interactions with the Emory Center for Neurodegenerative Disease, and the Yerkes National Primate Center. Our 5 cores demonstrate remarkable productivity in recruiting patients from the culturally diverse clinical specialty programs at Emory and Grady Memorial Hospitals for participation in our ADRC registry, the autopsy program, and the various clinical research activities. Data from these cores are captured and stored for distribution to local researchers and for national collaborations. Our biospecimen banks include well-characterized neuropathological case materials, and DNA, CSF, and blood samples from our clinical populations. These valuable resources are distributed widely for a variety of approved studies of genetic, molecular, pharmacological, and pathological investigations. The ADRC educational programs reach a broad audience of students, health care professionals, and the public. We propose three cutting edge research projects that are closely integrated with ADRC Cores: Project 1 (Dr. Ben Hampstead) """"""""Comparison of Memory Rehabilitation Techniques in Mild Cognitive Impairment"""""""", will use a novel approach to rehabilitation of memory combining behavioral components with functional brain imaging to address whether rehabilitation techniques target the intended brain regions and to determine the signature of brain activity associated with successful rehabilitation. Project 2, """"""""miRNA Expression Modulation of Alzheimer Disease Pathogenesis"""""""" (Dr. Peng Jin) will extend studies of miRNAs selectively altered in AD brain and evaluate their role in the post-transcriptional regulation of the expression of specific mRNAs that are involved in AD pathogenesis. Project 3, """"""""Norepinephrine-TrkB Interactions in Alzheimer's Disease"""""""" (Dr. David Weinshenker) studies a novel interaction between catecholamines and the TrkB receptor in animal and cell culture models of AD, as well as in brain tissues obtained from controls, MCI, and AD cases. Collectively, these projects span clinical, translational, and basic science research and will advance our understanding of cognition in normal aging and its transitions to mild cognitive impairment, AD, and related neurodegenerative disorders.
Georgia has one of the fast growing elderly populations in the country, anticipating a major increase in AD and other age-related neurodegenerative conditions in the decades ahead. Advances in clinical care, research, and education are essential to successfully confront the challenge. Renewal of the Emory ADRC will sustain progress in better understanding disease pathogenesis, enable earlier identification of at-risk individuals, and catalyze development of more effective treatments.
|Rangaraju, Srikant; Raza, Syed Ali; Li, Noel Xiang'An et al. (2018) Differential Phagocytic Properties of CD45low Microglia and CD45high Brain Mononuclear Phagocytes-Activation and Age-Related Effects. Front Immunol 9:405|
|Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25|
|Chalermpalanupap, Termpanit; Schroeder, Jason P; Rorabaugh, Jacki M et al. (2018) Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. J Neurosci 38:74-92|
|Maezawa, Izumi; Nguyen, Hai M; Di Lucente, Jacopo et al. (2018) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain 141:596-612|
|Bishof, Isaac; Dammer, Eric B; Duong, Duc M et al. (2018) RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease. J Biol Chem 293:11047-11066|
|Peng, Katherine Y; Pérez-González, Rocío; Alldred, Melissa J et al. (2018) Apolipoprotein E4 genotype compromises brain exosome production. Brain :|
|Zhang, Qi; Ma, Cheng; Gearing, Marla et al. (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathol Commun 6:19|
|Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Umoh, Mfon E; Dammer, Eric B; Dai, Jingting et al. (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10:48-62|
Showing the most recent 10 out of 444 publications